专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016123581A1 CRYSTALLINE C21H22C12N4O2 MALONATE 审中-公开
标题翻译：晶体C21H22C12N4O2
公开(公告)号：WO2016123581A1
公开(公告)日：2016-08-04
申请号：PCT/US2016/015843
申请日：2016-01-29
申请人： BIOMED VALLEY DISCOVERIES, INC.
发明人： DECRESCENZO, Gary , WELSCH, Dean , SELBO, Jon G. , ALBERT, Ekaterina V. , RIGSBEE, Emily M.
IPC分类号： A61P37/00 , C07F9/58 , A61P25/00 , C07F9/6558
CPC分类号： C07D401/04 , A61K31/4439 , A61K45/06 , C07B2200/13 , C07C55/08
摘要： The present invention provides a malonate salt of a compound of formula (I), which is a crystalline salt. Also provided are pharmaceutical compositions that include the provided malonate salt and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
摘要翻译：本发明提供式（I）化合物的丙二酸盐，其为结晶盐。还提供了包括所提供的丙二酸盐的药物组合物和使用所提供的结晶形式和用于治疗癌症的药物组合物的方法。

2. 发明申请

WO2014186623A3 METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE 审中-公开
公开(公告)号：WO2014186623A3
公开(公告)日：2014-11-20
申请号：PCT/US2014/038268
申请日：2014-05-15
申请人： BIOMED VALLEY DISCOVERIES
发明人： ROIX, Jeffrey James , SAHA, Saurabh
IPC分类号： A61K31/55
摘要： The present invention provides, inter alia, methods for treating or ameliorating the effects of a Chagas disease. The methods include administering to a subject in need thereof an effective amount of a first active agent selected from the group consisting of a histamine-H1-receptor antagonist, a selective neutrophil elastase inhibitor, an ergot alkaloid derivative, an inhibitor of 3 β-hydroxysteroid dehydrogenase, a reversible acetylcholinesterase inhibitor, a protease inhibitor, an aldosterone antagonist, a naphthoquinone, and combinations thereof, and a second active agent, which is benznidazole. Also provided are compositions for treating or ameliorating the effects of a Chagas disease. The compositions include azelastine and benznidazole in amounts effective to treat or ameliorate the effect of a Chagas disease and a pharmaceutically acceptable carrier.

3. 发明申请

WO2014169087A2 TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY 审中-公开
标题翻译：治疗原发性脊髓灰质炎
公开(公告)号：WO2014169087A2
公开(公告)日：2014-10-16
申请号：PCT/US2014/033585
申请日：2014-04-10
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK , LEE, Justin C. , HENDERSON, Christopher E.
发明人： LEE, Justin C. , HENDERSON, Christopher E.
IPC分类号： A61K31/522 , A61K31/519
CPC分类号： A61K48/00 , A61K31/165 , A61K31/192 , A61K31/4035 , A61K31/519 , A61K31/522 , A61K31/663 , A61K31/683 , A61K31/7088 , A61K38/10 , A61K38/13 , A61K45/06
摘要： The present invention provides, inter alia, methods and pharmaceutical compositions for treating or ameliorating an effect of proximal spinal muscular atrophy (SMA) and methods for preventing or slowing motor neuron death in a subject having SMA. The methods include administering to a subject in need thereof a modulator of a gene selected from the group consisting of phosphodiesterase 1c (Pde1c), Calbindin 2 (Calb2), Egl nine homolog 3 (Egl3), Metabotropic glutamate receptor 8 (mGluR8), Synaptotagmin 1 (Syt1), CUGBP, Elav-like family member 4 (Celf4), and combinations thereof in an amount effective to treat or ameliorate an effect of SMA. Also provided are methods for preventing or slowing motor neuron death.
摘要翻译：本发明尤其提供用于治疗或改善近端脊髓性肌萎缩（SMA）的作用的方法和药物组合物以及用于预防或减缓具有SMA的受试者运动神经元死亡的方法。所述方法包括向有需要的受试者施用选自磷酸二酯酶1c（Pde1c），Calbindin 2（Calb2），Egl9同系物3（Egl3），代谢型谷氨酸受体8（mGluR8），Synaptotagmin 1（Syt1），CUGBP，Elav样家族成员4（Celf4）及其组合，其量有效治疗或改善SMA的作用。还提供了用于预防或减缓运动神经元死亡的方法。

4. 发明申请

WO2014152220A1 IDENTIFICATION OF CANDIDATE TARGET GENES FOR TREATING NEOPLASIA 审中-公开
标题翻译：鉴定用于治疗NEOPLASIA的候选靶基因
公开(公告)号：WO2014152220A1
公开(公告)日：2014-09-25
申请号：PCT/US2014/027087
申请日：2014-03-14
申请人： BIOMED VALLEY DISCOVERIES, INC.
发明人： HALSE, Reza , SAHA, Saurabh , ROIX, Jeffrey
IPC分类号： G01N33/574
CPC分类号： G01N33/57484 , G01N33/5748
摘要： The present invention provides, inter alia, a method for identifying a target for treating a neoplasia. This method includes: (a) generating a second neoplastic cell line having a single gene knockdown from a first neoplastic cell line; (b) growing cells from the first and second neoplastic cell lines in vitro and in vivo ; (c) determining whether there is a difference with respect to a cancer marker between the first and second neoplastic cell lines grown in vitro; (d) determining whether there is a difference with respect to the same cancer marker in step (c) between the first and second neoplastic cell lines grown in vivo , wherein (i) if there is no difference in step (c) between the first and second neoplastic cell lines grown in vitro with respect to the cancer marker and (ii) there is a difference in step (d) between the first and second neoplastic cell lines grown in vivo with respect to the cancer marker, then the gene that is knocked down in the second cancer cell line is a target for treating a neoplasia. Methods and kits for identifying a candidate agent that may be useful for treating a neoplasia are also provided.
摘要翻译：本发明尤其提供了用于鉴定用于治疗瘤形成的靶的方法。该方法包括：（a）产生具有来自第一肿瘤细胞系的单个基因敲除的第二肿瘤细胞系; （b）体外和体内从第一和第二肿瘤细胞系生长细胞; （c）确定在体外生长的第一和第二肿瘤细胞系之间是否存在与癌症标志物的差异; （d）确定在体内生长的第一和第二肿瘤细胞系之间是否在步骤（c）中相同的癌症标志物是否存在差异，其中（i）如果在第一和相对于癌症标志物在体外生长的第二肿瘤细胞系和（ii）在体内生长的第一和第二肿瘤细胞系之间在癌症标志物上的步骤（d）之间存在差异，则基因是在第二癌细胞系中被击倒是治疗瘤形成的靶标。还提供了用于鉴定可用于治疗瘤形成的候选药物的方法和试剂盒。

5. 发明申请

WO2014022454A1 ORGANOCATALYTIC CARBONYL-OLEFIN AND OLEFIN-OLEFIN METATHESIS 审中-公开
标题翻译：有机碳 - 烯烃和烯烃 - 烯烃元素
公开(公告)号：WO2014022454A1
公开(公告)日：2014-02-06
申请号：PCT/US2013/052818
申请日：2013-07-31
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK , LAMBERT, Tristan Hayes , GRIFFITH, Allison , VANOS, Christine
发明人： LAMBERT, Tristan Hayes , GRIFFITH, Allison , VANOS, Christine
IPC分类号： C07C6/02 , B01J31/02
CPC分类号： C07D487/08 , B01J31/0237 , B01J2231/54 , B01J2231/543 , C07C45/69 , C07D209/52 , C07D231/04 , C07D307/46 , C07D333/22 , C07D491/18 , C07D491/22 , C07C47/21
摘要： The present invention provides, inter alia, organocatalytic carbonyl-olefin metathesis process. This process involves contacting a carbonyl-containing moiety with an olefin-containing moiety in the presence of a catalyst and under conditions sufficient to form a metathesis product with the proviso that the process takes place in the absence of photochemical promotion, stoichiometric amounts of transition metals, and Brnsted and Lewis acid catalysts. The present invention also provides an organocatalytic olefin-olefin metathesis process. This process involves contacting a first olefin-containing moiety with a second olefin-containing moiety in the presence of a catalyst and under conditions sufficient to form a metathesis product with the proviso that the process takes place in the absence of stoichiometric amounts of transition metals. Products made by the processes disclosed herein are also provided.
摘要翻译：本发明尤其提供了有机催化羰基 - 烯烃复分解方法。该方法包括在催化剂存在下和在足以形成复分解产物的条件下使含羰基部分与含烯烃部分接触，条件是该过程在不进行光化学促进的情况下进行，化学计量的过渡金属，和Brnsted和Lewis酸催化剂。本发明还提供了一种有机催化烯烃复分解方法。该方法包括在催化剂存在下和足以形成复分解产物的条件下使第一含烯烃部分与第二含烯烃部分接触，条件是该方法在不存在化学计量量的过渡金属的情况下进行。还提供了通过本文公开的方法制备的产品。

6. 发明申请

WO2013049045A1 COMPOSITIONS AND METHODS OF TREATING GLIOMAS 审中-公开
标题翻译：组合物和治疗玻璃体的方法
公开(公告)号：WO2013049045A1
公开(公告)日：2013-04-04
申请号：PCT/US2012/057085
申请日：2012-09-25
申请人： BIOMED VALLEY DISCOVERIES, INC. , HALSE, Reza , SAHA, Saurabh , ROIX, Jeffrey, James
发明人： HALSE, Reza , SAHA, Saurabh , ROIX, Jeffrey, James
IPC分类号： A61K45/00
CPC分类号： A61K38/08 , A61K31/137 , A61K31/155 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/197 , A61K31/235 , A61K31/401 , A61K31/403 , A61K31/404 , A61K31/4045 , A61K31/41 , A61K31/4168 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/42 , A61K31/433 , A61K31/4422 , A61K31/472 , A61K31/517 , A61K31/5415 , A61K31/55 , A61K31/554 , A61K31/675 , A61K38/12 , A61K38/13 , A61K45/06 , A61K2300/00
摘要： The present invention provides, inter alia, methods for treating or ameliorating the effects of a glioma. Methods of this invention include administering to a subject in need thereof an effective amount of a first active agent, such as e.g., an angiotensin receptor blocker, an antifungal agent, a bisphosphonate, an oxytocin inhibitor, an interleukin-1 (IL-1 ) inhibitor, a cyclooxygenase inhibitor, an α2δ voltage-dependent calcium channel (VDCC) inhibitor, a dihydroorotate dehydrogenase inhibitor, a calcium channel blocker, a renal sodium-chloride symporter inhibitor, an a2 adrenergic agonist, a phenothiazine antipsychotic, a calcineurin inhibitor, a 5-HT agonist, an angiotensin-converting enzyme (ACE) inhibitor, a direct rennin inhibitor, or combinations thereof, and a second active agent, which is a chemotherapeutic agent. Compositions for treating or ameliorating the effects of a glioma are also provided.
摘要翻译：本发明尤其提供了用于治疗或改善胶质瘤的作用的方法。本发明的方法包括向有需要的受试者施用有效量的第一活性剂，例如血管紧张素受体阻断剂，抗真菌剂，双膦酸盐，催产素抑制剂，白细胞介素-1（IL-1）抑制剂，环氧合酶抑制剂，α2delta电压依赖性钙通道（VDCC）抑制剂，二氢乳清酸脱氢酶抑制剂，钙通道阻断剂，肾钠氯化合物抑制剂，a2肾上腺素能激动剂，吩噻嗪抗精神病药，钙调磷酸酶抑制剂， 5-HT激动剂，血管紧张素转换酶（ACE）抑制剂，直接肾素抑制剂或其组合，以及作为化学治疗剂的第二活性剂。还提供了用于治疗或改善胶质瘤的作用的组合物。

7. 发明申请

WO2010008568A1 TM4SF4 AND MODULATORS THEREOF AND METHODS FOR THEIR USE 审中-公开
标题翻译： TM4SF4及其调制器及其使用方法
公开(公告)号：WO2010008568A1
公开(公告)日：2010-01-21
申请号：PCT/US2009/004121
申请日：2009-07-15
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK , SUSSEL, Lori , ANDERSON, Keith, Robert
发明人： SUSSEL, Lori , ANDERSON, Keith, Robert
IPC分类号： A61K48/00 , C12N5/00
CPC分类号： C12N15/1138 , C12N2310/11 , C12N2310/3233
摘要： The present invention relates to methods for modulating a β-cell population using a TM4SF4 modulator or a modulator of a TM4SF4 homolog. More particularly, the invention relates, inter alia, to methods and compositions for generating, expanding, and maintaining a β-cell population and treatment of diseases associated with the loss of β-cells using a TM4SF4 modulator or a modulator of a TM4SF4 homolog.
摘要翻译：本发明涉及使用TM4SF4调节剂或TM4SF4同源物的调节剂调节β细胞群体的方法。更具体地，本发明特别涉及用于产生，扩增和维持β细胞群体并使用TM4SF4调节剂或TM4SF4同源物的调节剂治疗与β细胞丧失相关的疾病的方法和组合物。

8. 发明申请

WO2005044196A3 NOVEL MODULATORS OF AMYLOID-BETA PRODUCTION AND USES THEREOF 审中-公开
公开(公告)号：WO2005044196A3
公开(公告)日：2005-05-19
申请号：PCT/US2004/036459
申请日：2004-11-01
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK , KIM, Tae-Wan , LEE, Hahn-Jun
发明人： KIM, Tae-Wan , LEE, Hahn-Jun
IPC分类号： C07H21/02 , C07H21/04 , C07K14/435 , C07K16/18 , C12N15/63 , A01K67/00 , C12Q1/68 , A61K38/00 , A61K31/713
摘要： The present invention provides isolated nucleic acid sequences encoding presenilin stabilization factor (PSF) and PSF-like (PSFL) protein, vectors comprising same, host cells transformed with the vectors, and transgenic animals containing the host cells. The present invention further provides purified PSF and PSFL polypeptides, methods for making same, and pharmaceutical compositions comprising the polypeptides. Also provided are agents reactive with the nucleic acid sequences and polypeptides, kits comprising same, and methods for producing same. The present invention further provides methods for decreasing amyloid-beta (Aß) production, destabilizing presenilin or nicastrin, destabilizing a gamma-secretase complex, and inhibiting activity of gamma-secretase, and pharmaceutical compositions for accomplishing same. The present invention further provides methods for treating neurodegeneration in a subject. Finally, the present invention provides an in vitro system for identifying an agent that modulates production of Aß or an Aß precursor, methods for making and using same, and agents identified by same.

9. 发明申请

WO2017127721A1 PREVENTION OF SSRI-INDUCED GASTROINTESTINAL DYSFUNCTION WITH A 5-HT4 RECEPTOR ANTAGONIST 审中-公开
标题翻译：用5-HT4受体拮抗剂预防SSRI诱导的胃肠功能障碍
公开(公告)号：WO2017127721A1
公开(公告)日：2017-07-27
申请号：PCT/US2017/014394
申请日：2017-01-20
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
发明人： MARGOLIS, Kara G. , GERSHON, Michael D.
IPC分类号： A01N43/90 , A61K31/535 , A61K38/00
CPC分类号： A61K31/55 , A61K31/4178 , A61K31/5365 , A61K36/28 , A61K38/00
摘要： The present invention provides, inter alia , methods for treating or preventing a disorder in a subject exposed to an agent that antagonizes the serotonin reuptake transporter (SERT), such as an SSRI, in utero or by consumption by the subject of breast milk from the subject's mother, by administering a 5-HT4 receptor antagonist, for example, to the subject's mother.
摘要翻译：本发明提供了用于治疗或预防暴露于拮抗5-羟色胺再摄取转运蛋白的药剂的受试者中的病症的方法，尤其是用于治疗或预防受试者中的病症的方法。（SERT），例如SSRI，或者通过给受试者母亲施用5-HT 4受体拮抗剂，通过受试者母亲的乳汁受试者摄入。 / p>

10. 发明申请

WO2016100911A1 METHODS AND KITS FOR IDENTIFYING POLYPEPTIDE BINDING SITES IN A GENOME 审中-公开
标题翻译：识别基因组中多肽结合位点的方法和工具
公开(公告)号：WO2016100911A1
公开(公告)日：2016-06-23
申请号：PCT/US2015/066861
申请日：2015-12-18
申请人： STOWERS INSTITUTE FOR MEDICAL RESEARCH
发明人： ZEITLINGER, Julia , HE, Qiye , JOHNSTON, Jeff
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6869 , C12Q1/6806 , C12Q1/6853 , C12Q2535/122 , C12Q2537/159 , C12Q2563/179
摘要： The present invention provides, inter alia, methods and kits for identifying where a polypeptide of interest binds in a genome. The methods include a) carrying out a chromatin immunoprecipitation coupled to exonuclease digestion (ChIP-exo) process with an antibody against the polypeptide of interest; (b) extracting a polynucleotide fragment to which the polypeptide of interest binds; (c) carrying out a library preparation protocol adapted from an individual nucleotide resolution UV cross-linking and immunoprecipitation (iCLIP) process on the ChIP-exo processed polynucleotide fragment; and (d) sequencing the resulting polynucleotides. The kits include: (a) reagents sufficient to carry out ChIP-exo; (b) reagents sufficient to carry out the library preparation protocol adapted from the iCLIP process; and (c) instructions for use.
摘要翻译：本发明尤其提供用于鉴定目的多肽在基因组中结合的位置的方法和试剂盒。所述方法包括a）使用与目标多肽的抗体进行与核酸外切酶消化（ChIP-exo）偶联的染色质免疫沉淀; （b）提取目标多肽所结合的多核苷酸片段; （c）在ChIP-exo处理的多核苷酸片段上进行改编自单个核苷酸决定的UV交联和免疫沉淀（iCLIP）方法的文库制备方案; 和（d）测序得到的多核苷酸。试剂盒包括：（a）足以进行ChIP-exo的试剂; （b）足以执行改编自iCLIP方法的文库制备方案的试剂; 和（c）使用说明。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式